New Migraine Drugs Tied to Less Risk for Adverse Events |
Journal Updates
eMediNexus Coverage from: 
New Migraine Drugs Tied to Less Risk for Adverse Events

0 Read Comments                

According to a new systematic review and meta-analysis, new classes of antimigraine drugs appear to be effective and have improved tolerability among patients with chronic migraine.Investigators compared the outcomes for acute migraine management using lasmiditan (a 5-hydroxytryptamine [5HT]1F–receptor agonist), and gepants - rimegepant and ubrogepant (calcitonin gene–related peptide [CGRP] antagonists) - with standard triptan (selective 5-HT1B/1D–receptor agonist) treatment. T...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now